Clinical Trial Update: PPARGC1β and CNTN4 Genotype Aspirin Study [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update investigating whether PPARGC1β and CNTN4 genotypes influence aspirin effects in cardiovascular disease; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Royal College of Surgeons, Ireland | Conditions: Cardiovascular Diseases | Phase 4 | Status: UNKNOWN